Peter Jenner

London, ENG SE11UL, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 96 publications

Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers.

Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: June 01, 2026

Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptors.

Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptors.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: August 01, 2025

COMT inhibition with entacapone for patients with Parkinson's disease and motor complications: the novelty of continuous infusion.

COMT inhibition with entacapone for patients with Parkinson's disease and motor complications: the novelty of continuous infusion.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: July 21, 2025

Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson's disease.

Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson's disease.

Journal: Clinical parkinsonism & related disorders

Published: November 28, 2024

How and why the adenosine A2A receptor became a target for Parkinson's disease therapy.

How and why the adenosine A2A receptor became a target for Parkinson's disease therapy.

Journal: International review of neurobiology

Published: September 23, 2023

Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson's disease?

Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson's disease?

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: August 09, 2023

The 20th anniversary of the first clinical use of Stalevo®.

The 20th anniversary of the first clinical use of Stalevo®.

Journal: European journal of neurology

Published: June 26, 2023

Stalevo® : A pioneering treatment for OFF periods in Parkinsons disease.

Stalevo® : A pioneering treatment for OFF periods in Parkinsons disease.

Journal: European journal of neurology

Published: June 26, 2023

Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.

Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: April 04, 2023

Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson's Disease.

Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson's Disease.

Journal: Current neuropharmacology

Published: February 23, 2023

Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease.

Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease.

Journal: European journal of neurology

Published: December 27, 2022

Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals.

Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: October 28, 2022

Showing 1-12 of 96

Last Updated: 09/26/2026